Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Chemotherapy for advanced colorectal cancer

In a study published in the latest Lancet Oncology, systemic adjuvant chemotherapy is shown useful in the treatment of advanced colorectal cancer, resulting in improved survival and reducing metastases.

News image

fiogf49gjkf04

Systemic adjuvant chemotherapy can improve overall survival and reduce the incidence of distant metastases for patients with advanced colon cancer.

Dr Bernard Nordlinger and colleagues investigated survival and recurrence for patients with stage II to III colorectal cancer.

The team considered whether regional chemotherapy combined with systemic chemotherapy was more effective than was systemic chemotherapy alone.

5-year survival was 72% for patients assigned regional and systemic chemotherapy
Lancet Oncology

The investigators also compared systemic chemotherapy with fluorouracil and folinic acid with that of fluorouracil and levamisole.

The investigative team randomly assigned 753 patients during surgery, with stage II to III colorectal cancer.

Patients were randomized either to systemic chemotherapy alone, of which 379 received fluorouracil and folinic acid in Group 1, and 374 received fluorouracil and levamisole in Group 2.

The team also randomized 748 patients to postoperative regional chemotherapy with fluorouracil followed by systemic chemotherapy and with further randomization into Groups 3 and 4.

Group 3 consisted of 368 patients who received fluorouracil and folinic acid and 380 in Group 4 received fluorouracil and levamisole.

The investigators reported that tegional chemotherapy was given intraperitoneally to 415 or intraportally to 235 patients according to institution.

The primary endpoint was 5-year overall survival whilst secondary endpoints were 5-year disease-free survival and toxic effects.

The investigative team undertook analyses by intention to treat.

The investigators reported a median follow-up of 7 years.

The 5-year overall survival was 72% for patients assigned regional and systemic chemotherapy, compared with 72% for systemic chemotherapy alone.

The team also found that 5-year overall survival for all patients assigned fluorouracil and levamisole was 72%.

In addition, the 5-year overall survival for all those assigned fluorouracil and folinic acid was 72.3%.

The team noted that the hazard ratios for 5-year disease-free survival were 0.94 for regional versus non-regional treatment.

The investigators also noted that the hazard ratios for all fluorouracil and levamisole versus fluorouracil and folinic acid were 0.92.

The team found that Grade 3 to 4 toxic effects were low in all groups.

Dr Nordlinger's team concludes, “Fluorouracil-based regional chemotherapy adds no further benefit to that obtained with systemic chemotherapy alone in patients with advanced colorectal cancer.”

Lancet Oncol 2005: Early Online Publication, 21 June, DOI:10.1016/S1470-2045(05)70222-9
27 June 2005

Go to top of page Email this page Email this page to a colleague

 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
c-Myc expression and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us